Intra-Cellular Therapies

ITI, Takeda in collaboration

Thursday, March 3, 2011

Intra-Cellular Therapies has entered into a preclinical discovery deal with Takeda to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors for cognitive impairment associated with schizophrenia and a variety of psychiatric and neurological diseases, according to FierceBiotech.

[Read More]